Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 9/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9359788 | 0.87 | NLRP3 (0.78) | NLRP3POLBKDM4EGLAMAPK1 | |
| SCHEMBL9104962 | 0.86 | NLRP3 (0.62) | NLRP3POLBKDM4EGLAMAPK1 | |
| SCHEMBL6929631 | 0.85 | NPC1 (0.63) | NLRP3POLBKDM4ELMNAHSD17B10 | |
| SCHEMBL11520630 | 0.85 | KDM4E (0.55) | NLRP3POLBKDM4EGLAMAPK1 | |
| SCHEMBL11624236 | 0.85 | NLRP3 (0.63) | NLRP3POLBKDM4EGLAMAPK1 | |
| SCHEMBL27570537 | 0.81 | NLRP3 (0.61) | NLRP3POLBKDM4EGLAMAPK1 | |
| SCHEMBL9958891 | 0.81 | POLB (0.60) | POLBKDM4EMAPK1LMNAMAPT | |
| SCHEMBL1024873 | 0.81 | NLRP3 (0.65) | NLRP3POLBKDM4EGLAMAPK1 | |
| SCHEMBL4955341 | 0.80 | NLRP3 (0.47) | NLRP3POLBKDM4ELMNAMAPT | |
| SCHEMBL12884719 | 0.80 | POLB (0.53) | NLRP3POLBKDM4ELMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4508025-A1 | METHODS FOR THE PREPARATION OF 5-CHLORO-2- ((ETHOXYCARBONYL)AMINO)-3-METHYLBENZOIC ACID | FMC Corporation (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-119183449-A | Method for producing 5-chloro-2- ((ethoxycarbonyl) amino) -3-methylbenzoic acid | FMC公司 | 2024-12-24 | — | — | CN | disclosed |
| WO-2023200913-A1 | METHODS FOR THE PREPARATION OF 5-CHLORO-2- ((ETHOXYCARBONYL)AMINO)-3-METHYLBENZOIC ACID | FMC CORPORATION (US) | 2023-10-19 | — | — | WO | disclosed |
| CN-116670115-A | Process for preparing anthranilic acid/anthranilic acid amide compounds and intermediates thereof | 皮埃企业有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-2394983-B1 | Process for making 3-substituted 2-amino-5-halobenzamides | DU PONT (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2044002-B1 | PROCESS FOR MAKING 3-SUBSTITUTED 2-AMINO-5-HALOBENZAMIDES | DU PONT (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8153844-B2 | Process for making 3-substituted 2-amino-5-halobenzamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2394983-A1 | Process for making 3-substituted 2-amino-5-halobenzamides | E.I. Du Pont De Nemours And Company (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20090306372-A1 | Process for Making 3-Substituted 2-Amino-5-Halobenzamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-12-10 | — | — | US | disclosed |
| EP-2044002-A2 | PROCESS FOR MAKING 3-SUBSTITUTED 2-AMINO-5-HALOBENZAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010897-A2 | PROCESS FOR MAKING 3-SUBSTITUTED 2-AMINO-5-HALOBENZAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306372-A1 | Process for Making 3-Substituted 2-Amino-5-Halobenzamides | C5, CD79B, C9 | NLRP3 4841/4885POLB 1298/4885KDM4E 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.